PROGRESS-AD OLE StudySchedule of Activities
Select the participant’s visit below. View the table of abbreviations here.
Treatment Period: Year 1 and 2
Allowed interval: ± 7 days, and consecutive dosing visits must be 3 to 5 weeks apart.
Early Treatment/Study Discontinuation
Within 4 weeks after the last dose or at the time of withdrawing from the study.
Follow-up
12 weeks after the final dose at Week 100 or 8 weeks after Week 104 if study treatment has been discontinued early.